Effects of glycemic indicators on early neurological outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis.

Zuo-Wei Duan, Zhi-Ning Li, Yu-Jia Zhai, Teng-Fei Liu, Cui-Cui Zhang, Ting Hu, Xiu-E Wei, Liang-Qun Rong, Hai-Yan Liu
Author Information
  1. Zuo-Wei Duan: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China.
  2. Zhi-Ning Li: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China.
  3. Yu-Jia Zhai: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China.
  4. Teng-Fei Liu: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China.
  5. Cui-Cui Zhang: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China.
  6. Ting Hu: Department of Neurology, Medical School of Nanjing University, Xuzhou 221006, Jiangsu Province, China.
  7. Xiu-E Wei: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China.
  8. Liang-Qun Rong: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China.
  9. Hai-Yan Liu: Department of Neurology, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou 221006, Jiangsu Province, China. sjnklhy0722@163.com.

Abstract

BACKGROUND: Stress hyperglycemia (SH) is a common phenomenon that is present in about 50% of patients with acute ischemic stroke (AIS). It is thought to be a main risk factor for poor functional outcome among patients with AIS undergoing intravenous thrombolysis (IVT).
AIM: To investigate the predictive value of glycemic indicators for early neurological outcomes (ENOs) in patients with AIS treated with IVT.
METHODS: We retrospectively reviewed a prospectively collected database of patients with AIS who underwent IVT at the Department of Neurology, Second Affiliated Hospital of Xuzhou Medical University, between January 2017 and June 2022. ENO included early neurological improvement (ENI) and early neurological deterioration (END), defined as a decrease or increase in the National Institutes of Health Stroke Scale (NIHSS) score between baseline and 24 hours after IVT. We analyzed the associations between glycemic indicators [including admission hyperglycemia (AH), fasting blood glucose (FBG), and SH ratio (SHR)] and ENO in all patients and in subgroups stratified by diabetes mellitus (DM).
RESULTS: A total of 819 patients with AIS treated with IVT were included. Among these, AH was observed in 329 patients (40.2%). Compared with patients without AH, those with AH were more likely to have a higher prevalence of DM ( < 0.001) and hypertension ( = 0.031) and presented with higher admission NIHSS scores ( < 0.001). During the first 24 hours after IVT, END occurred in 208 patients (25.4%) and ENI occurred in 156 patients (19.0%). Multivariate mixed logistic regression analyses indicated that END was independently associated with AH [odds ratio (OR): 1.744, 95% confidence interval (CI): 1.236-2.463; = 0.002]. Subjects were classified into four groups representing quartiles. Compared with Q1, patients in the higher quartiles of SHR (Q2: OR: 2.306, 95%CI: 1.342-3.960; = 0.002) (Q3: OR: 2.284, 95%CI: 1.346-3.876; = 0.002) (Q4: OR: 3.486, 95%CI: 2.088-5.820; = 0.001) and FBG (Q3: OR: 1.746, 95%CI: 1.045-2.917; = 0.033) (Q4: OR: 2.436, 95%CI: 1.476-4.022; = 0.001) had a significantly higher risk of END in the overall population. However, none of the glycemic indicators were found to be associated with ENI in patients with or without DM.
CONCLUSION: Our study demonstrated that glycemic indicators in patients with stroke treated with IVT were associated with the presence of END rather than ENI during the first 24 hours after admission.

Keywords

References

  1. Cerebrovasc Dis. 2022;51(3):331-337 [PMID: 34638120]
  2. Stroke. 2020 Nov;51(11):3215-3223 [PMID: 33054674]
  3. Neurology. 2021 Oct 4;97(14):e1437-e1446 [PMID: 34400585]
  4. Lancet. 2008 Oct 11;372(9646):1303-9 [PMID: 18790527]
  5. Postgrad Med. 2019 Sep;131(7):423-437 [PMID: 31382796]
  6. Stroke. 1999 Jan;30(1):160-70 [PMID: 9880405]
  7. Front Aging Neurosci. 2022 Feb 08;14:782282 [PMID: 35211004]
  8. Front Neurol. 2022 Mar 07;13:809066 [PMID: 35321507]
  9. J Clin Hypertens (Greenwich). 2022 Aug;24(8):1086-1094 [PMID: 35880473]
  10. J Thromb Thrombolysis. 2020 Jan;49(1):67-74 [PMID: 31482326]
  11. Diabetes Care. 2008 Aug;31(8):1473-8 [PMID: 18540046]
  12. Int J Stroke. 2015 Oct;10(7):1087-92 [PMID: 26332252]
  13. Front Neurol. 2022 Oct 17;13:1037663 [PMID: 36324389]
  14. J Stroke Cerebrovasc Dis. 2022 Dec;31(12):106847 [PMID: 36323166]
  15. Clin Interv Aging. 2021 Mar 09;16:431-442 [PMID: 33727806]
  16. J Stroke Cerebrovasc Dis. 2013 Nov;22(8):e590-6 [PMID: 23954601]
  17. BMC Neurol. 2024 Jan 2;24(1):13 [PMID: 38166660]
  18. Stroke. 2016 Jan;47(1):120-7 [PMID: 26658447]
  19. Oxid Med Cell Longev. 2021 Apr 7;2021:5545330 [PMID: 33897941]
  20. J Clin Endocrinol Metab. 2015 Dec;100(12):4490-7 [PMID: 26485219]
  21. CNS Neurosci Ther. 2013 Jan;19(1):43-7 [PMID: 23206165]
  22. BMC Neurol. 2022 Jun 7;22(1):212 [PMID: 35672740]
  23. Int J Stroke. 2011 Jun;6(3):211-2 [PMID: 21557807]
  24. Eur J Med Res. 2022 Aug 2;27(1):138 [PMID: 35918760]
  25. World J Diabetes. 2021 Dec 15;12(12):2096-2106 [PMID: 35047123]
  26. J Cereb Blood Flow Metab. 2007 Mar;27(3):435-51 [PMID: 16804552]
  27. Cerebrovasc Dis. 2012;34(2):140-6 [PMID: 22854333]
  28. J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):87-94 [PMID: 24970907]
  29. J Neuroradiol. 2015 Feb;42(1):30-46 [PMID: 25649921]
  30. Neurology. 1995 Nov;45(11):1975-9 [PMID: 7501144]
  31. Diabetes Care. 2010 Jul;33(7):1449-51 [PMID: 20357368]
  32. Lancet. 2015 Jan 10;385(9963):117-71 [PMID: 25530442]
  33. Stroke. 2001 Oct;32(10):2426-32 [PMID: 11588337]
  34. Front Neurol. 2022 Jan 13;12:785428 [PMID: 35095730]
  35. Cerebrovasc Dis. 2009;27 Suppl 1:148-55 [PMID: 19342845]
  36. J Neurointerv Surg. 2023 Jun;15(6):547-551 [PMID: 35636948]
  37. World J Diabetes. 2017 Jun 15;8(6):235-248 [PMID: 28694925]
  38. J Thromb Haemost. 2010 Aug;8(8):1663-9 [PMID: 20492456]
  39. Metabolism. 2017 Feb;67:99-105 [PMID: 28081783]
  40. PLoS One. 2022 Oct 31;17(10):e0277020 [PMID: 36315566]
  41. Oxid Med Cell Longev. 2022 Aug 17;2022:3363735 [PMID: 36035225]
  42. N Engl J Med. 2008 Sep 25;359(13):1317-29 [PMID: 18815396]
  43. Stroke. 2019 Dec;50(12):e344-e418 [PMID: 31662037]
  44. Lancet Reg Health West Pac. 2022 Jan 02;20:100370 [PMID: 35036978]
  45. Int J Stroke. 2012 Jun;7(4):321-9 [PMID: 22463492]
  46. Transl Stroke Res. 2018 Aug;9(4):347-355 [PMID: 29116527]

Word Cloud

Created with Highcharts 10.0.0patients0IVT=1neurologicalAISglycemicindicatorsENDAHOR:95%CI:hyperglycemiastrokeearlytreatedENIhigher0012Stressischemicthrombolysis24hoursadmissionratioDMassociatedSHacuteriskintravenousoutcomesENOincludedimprovementdeteriorationNIHSSFBGSHRComparedwithout<firstoccurred:quartiles002Q3:Q4:EarlyBACKGROUND:commonphenomenonpresent50%thoughtmainfactorpoorfunctionaloutcomeamongundergoingAIM:investigatepredictivevalueENOsMETHODS:retrospectivelyreviewedprospectivelycollecteddatabaseunderwentDepartmentNeurologySecondAffiliatedHospitalXuzhouMedicalUniversityJanuary2017June2022defineddecreaseincreaseNationalInstitutesHealthStrokeScalescorebaselineanalyzedassociations[includingfastingbloodglucose]subgroupsstratifieddiabetesmellitusRESULTS:total819Amongobserved329402%likelyprevalencehypertension031presentedscores208254%156190%Multivariatemixedlogisticregressionanalysesindicatedindependently[oddsOR74495%confidenceintervalCI236-2463002]SubjectsclassifiedfourgroupsrepresentingQ1Q2:306342-3960284346-38763486088-5820746045-2917033436476-4022significantlyoverallpopulationHowevernonefoundCONCLUSION:studydemonstratedpresenceratherEffectsAcuteIntravenous

Similar Articles

Cited By